Cargando…

Protective effect of urotensin II receptor antagonist urantide and exercise training on doxorubicin-induced cardiotoxicity

Doxorubicin (DOX) has a wide antitumor spectrum, but its adverse cardiotoxicity may lead to heart failure. Urotensin II (UII) is the most potent vasoconstrictor in mammals. It plays a role by activating the UII receptor (UT), the orphan G protein-coupled receptor (GPR14), collectively referred to as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Jing, Zhou, Jiedong, Sun, Shimin, Lin, Hui, Zhang, Hanlin, Zhong, Zuoquan, Chi, Jufang, Guo, HangYuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870887/ https://www.ncbi.nlm.nih.gov/pubmed/36690700 http://dx.doi.org/10.1038/s41598-023-28437-y

Ejemplares similares

The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats
por: ZHAO, JUAN, et al.
Publicado: (2013)

Urotensin II and urantide exert opposite effects on the cellular components of atherosclerotic plaque in hypercholesterolemic rabbits
por: Yu, Qing-qing, et al.
Publicado: (2019)

Potential Clinical Implications of the Urotensin II Receptor Antagonists
por: Tsoukas, Philip, et al.
Publicado: (2011)

Inhibitory Effect of an Urotensin II Receptor Antagonist on Proinflammatory Activation Induced by Urotensin II in Human Vascular Endothelial Cells
por: Park, Sung Lyea, et al.
Publicado: (2013)

Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma
por: Portnoy, Alison, et al.
Publicado: (2013)

Machine learning algorithms identifying the risk of new-onset ACS in patients with type 2 diabetes mellitus: A retrospective cohort study
por: Zhong, Zuoquan, et al.
Publicado: (2022)

Yellow Wine Polyphenolic Compounds prevents Doxorubicin‐induced cardiotoxicity through activation of the Nrf2 signalling pathway
por: Lin, Hui, et al.
Publicado: (2019)

Repair effect of the poly (D,L-lactic acid) nanoparticle containing tauroursodeoxycholic acid-eluting stents on endothelial injury after stent implantation
por: Zhou, Jiedong, et al.
Publicado: (2022)

Urotensin II in cardiovascular regulation
por: Russell, Fraser D
Publicado: (2008)

Exercise Training Preserves Myocardial Strain and Improves Exercise Tolerance in Doxorubicin-Induced Cardiotoxicity
por: Gomes-Santos, Igor L., et al.
Publicado: (2021)

Central and Peripheral Effects of Urotensin II and Urotensin II-Related Peptides on Cardiac Baroreflex Sensitivity in Trout
por: Lancien, Frédéric, et al.
Publicado: (2017)

Identification and verification of immune-related biomarkers and immune infiltration in diabetic heart failure
por: Zhong, Zuoquan, et al.
Publicado: (2022)

The beneficial role of exercise in preventing doxorubicin-induced cardiotoxicity
por: Gaytan, Samantha L., et al.
Publicado: (2023)

Divergent cardio-ventilatory and locomotor effects of centrally and peripherally administered urotensin II and urotensin II-related peptides in trout
por: Vanegas, Gilmer, et al.
Publicado: (2015)

The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure
por: Nishi, Mina, et al.
Publicado: (2020)

The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity
por: Akolkar, Gauri, et al.
Publicado: (2015)

Effects of Calorie Restriction and Voluntary Exercise on Doxorubicin-Induced Cardiotoxicity
por: Hall, Stephanie E., et al.
Publicado: (2019)

Exercise intervention decreases acute and late doxorubicin‐induced cardiotoxicity
por: Wang, Fei, et al.
Publicado: (2021)

Role of acetylation in doxorubicin-induced cardiotoxicity
por: Li, Daisong, et al.
Publicado: (2021)

The peptide compound urantide regulates collagen metabolism in atherosclerotic rat hearts and inhibits the JAK2/STAT3 pathway
por: Wang, Tu, et al.
Publicado: (2020)

Urotensin II Promotes Atherosclerosis in Cholesterol-Fed Rabbits
por: Li, Yafeng, et al.
Publicado: (2014)

Urotensin-II: More Than a Mediator for Kidney
por: Balat, Ayşe, et al.
Publicado: (2012)

Blockade of Urotensin II Receptor Prevents Vascular Dysfunction
por: Kim, Young-Ae, et al.
Publicado: (2016)

Role of Urotensin-II in Saphenous Vein Graft Disease
por: Tüysüz, Mehmet Erin, et al.
Publicado: (2020)

Urotensin II levels in patients with inflammatory bowel disease
por: Alicic, Damir, et al.
Publicado: (2021)

Urantide decreases hepatic steatosis in rats with experimental atherosclerosis via the MAPK/Erk/JNK pathway
por: Cui, Haipeng, et al.
Publicado: (2021)

Urotensin II Inhibits Doxorubicin-Induced Human Umbilical Vein Endothelial Cell Death by Modulating ATF Expression and via the ERK and Akt Pathway
por: Chen, Yen-Ling, et al.
Publicado: (2014)

Identification of new target proteins of a Urotensin-II receptor antagonist using transcriptome-based drug repositioning approach
por: Lim, Gyutae, et al.
Publicado: (2021)

INKing the Cardiotoxicity Out of Doxorubicin
por: Guo, Zhen, et al.
Publicado: (2023)

Urantide prevents CCl4-induced acute liver injury in rats by regulating the MAPK signalling pathway
por: Li, Ying, et al.
Publicado: (2021)

Functional components of Chinese rice wine can ameliorate diabetic cardiomyopathy through the modulation of autophagy, apoptosis, gut microbiota, and metabolites
por: Yang, Jinjin, et al.
Publicado: (2022)

A Novel Urotensin II Receptor Antagonist, KR-36996 Inhibits Smooth Muscle Proliferation through ERK/ROS Pathway
por: Kim, Tae-Ho, et al.
Publicado: (2017)

Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures
por: Merlino, Francesco, et al.
Publicado: (2013)

A closer look at the role of urotensin II in the metabolic syndrome
por: Barrette, Pierre-Olivier, et al.
Publicado: (2012)

Urotensin II in Invertebrates: From Structure to Function in Aplysia californica
por: Romanova, Elena V., et al.
Publicado: (2012)

Irisin levels are associated with urotensin II levels in diabetic patients
por: He, Wan-Yu, et al.
Publicado: (2015)

The Role of Urotensin-II in Obesity and Metabolic Syndrome in Pediatric Population
por: Simunovic, Marko, et al.
Publicado: (2022)

Urotensin II level is elevated in inflammatory bowel disease patients
por: Zhang, Yan, et al.
Publicado: (2022)

Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction
por: Ogawa, Akiko, et al.
Publicado: (2023)

Lycopene Inhibits Urotensin-II-Induced Cardiomyocyte Hypertrophy in Neonatal Rat Cardiomyocytes
por: Chao, Hung-Hsing, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_oterelmoprun528qrp0re7vopv